Jacobs Levy Equity Management
TERN

Jacobs Levy Equity Management’s Terns Pharmaceuticals TERN Stock Holding History

Jacobs Levy Equity Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-136,979
Closed -$1.03M – 1056
2025
Q3 		$1.03M Sell
136,979
-65,591
-32% -$419K ﹤0.01% 711
2025
Q2 		$756K Sell
202,570
-292,307
-59% -$913K ﹤0.01% 813
2025
Q1 		$1.37M Buy
+494,877
New +$2.02M 0.01% 747
2022
Q1 		– Sell
-55,222
Closed -$390K – 1087
2021
Q4 		$390K Sell
55,222
-32,312
-37% -$269K ﹤0.01% 865
2021
Q3 		$912K Buy
87,534
+69,884
+396% +$725K 0.01% 766
2021
Q2 		$216K Buy
+17,650
New +$301K ﹤0.01% 975

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Jacobs Levy Equity Management's TERN Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 136,979 shares — an estimated $1.03M sold.

Jacobs Levy Equity Management first reported a position in TERN in Q2 2021 and held it in 6 quarters. The position peaked at $1.37M in Q1 2025. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

  • Jacobs Levy Equity Management reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 136,979 Terns Pharmaceuticals shares in Q4 2025, an estimated $1.03M.
  • Jacobs Levy Equity Management first reported a position in Terns Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Jacobs Levy Equity Management's Terns Pharmaceuticals position peaked at $1.37M in Q1 2025.
  • 248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.